Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erdosteine - Edmond Pharma

X
Drug Profile

Erdosteine - Edmond Pharma

Alternative Names: ALT 09; Asdigan; Biopulmin; Dostin; Dostol; Ectrin; Edirel; Erdomed; Erdopect; Erdos; Erdostin; Erdotin; Esteclin; Fluidasa; Flusten; KW 9144; Mucoflux; Mucofor; Mucotec; Mucothera; RV 144; Secresolv; Tusselin and Theovix; Tussol; Vectrine

Latest Information Update: 26 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Edmond Pharma
  • Developer Alitair Pharmaceuticals Inc; Edmond Pharma; Recipharm
  • Class Anti-inflammatories; Antibronchitics; Expectorants; Small molecules; Thioglycolates; Thiophenes
  • Mechanism of Action Antioxidants; Glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiectasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bronchitis
  • Phase III Chronic obstructive pulmonary disease
  • No development reported Bronchiectasis; COVID-19 pneumonia

Most Recent Events

  • 26 Dec 2022 No development reported - Clinical-Phase-Unknown for COVID-19 pneumonia in Italy (PO)
  • 14 Oct 2020 Efficacy data from clinical trials in COVID-2019 pneumonia released by Recipharm
  • 14 Oct 2020 Recipharm plans a clinical trial in COVID-2019 infections (Prevention)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top